🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06657573
Starting soon Not applicable

Vaccine Chatbot for Improving Influenza Vaccination Uptake

NCT06657573 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Not applicable
Started
2024-10-26
Last updated
2024-10-24

Condition(s) studied

Influenza Vaccines

Investigational drug(s) / intervention(s)

An AI-enabled chatbot tailored for influenza vaccine consultation

An AI-enabled chatbot tailored for influenza vaccine consultation: The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.

Study summary

This study aims to assess the impact of a vaccine chatbot on improving influenza vaccination uptake among children aged between 6 and 59 months through a cluster randomized trial. Specifically, the main questions it seeks to answer are whether an AI-enabled vaccine chatbot will increase the uptake of influenza vaccine among children and their family members, and how it will influence parents' literacy and confidence towards influenza vaccine. It will explore the potential role of vaccine chatbot on vaccination services.

A cluster randomization will be used to assign children to the intervention and control groups. Parents of children in the intervention group will be invited to use the influenza vaccine chatbot online through WeChat, the mostly widely used social media platform in mainland China, or any web browsers. They can ask any questions related to the influenza vaccine and receive validated answers from the chatbot immediately. The intervention will last one and a half months, with invitations sent every ten days to reinforce the engagement. The control group will not use the chatbot during the intervention duration. After the intervention, the uptake, literacy, and confidence towards influenza vaccine will be compared between the intervention and control groups to evaluate the impact of vaccine chatbot.

Eligibility

Sex
ALL
Min age
6 Months
Max age
59 Months
Healthy volunteers
Accepted
Inclusion Criteria: * Parents of the child visiting clinics. * Children aged between 6 and 59 months. * Children who have not received an influenza vaccine in both the current and previous flu seasons and have not yet made an appointment for an influenza vaccine. * Children who have no contraindications to receiving an influenza vaccine. * Provide informed consent and willing to participate throughout the study. Exclusion Criteria: * Children vaccinated or appointed for influenza vaccination or with any contraindication to influenza vaccine. * Parents with mental disorders or visual/reading impairments, and unable to cooperate with and undergo the intervention activities. * Unwilling to participate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hangzhou Center for Disease Control and Prevention Hangzhou Zhejiang

More Fudan University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06657573 on ClinicalTrials.gov ↗ ← All trials in China